CALCA and steatosis: Senomorphics that attenuate the SASP—for example, DMY acting via the KC miR‐155‐5p–SIRT1 axis—early restoration of NAD+ with nicotinamide to block acetaldehyde‐induced hepatocyte senescence, and activation of AMPK and SIRT1 pathways to mitigate hepatic OxS and steatosis collectively suppress senescence programs, with a more favorable tolerability profile than classical senolytics.